bioRxiv Science⌕ Search

bioRxiv · 10.1101/2023.08.18.553807

LncRNA SNHG16 modulates paclitaxel resistance in breast cancer by regulating Let-7a-5p/DUSP7

Abstract

ObjectiveTo investigate the effect of long chain non coding RNA (lncRNA) small nucleolar RNA host gene 6 (SNHG16) on paclitaxel (PTX) resistance in breast cancer and to understand its underlying mechanism, to lay a foundation for decreasing the PTX resistance in breast cancer treatment and improving the therapeutic quality for breast cancer patients. MethodsPTX was used to induce the establishment of PTX resistant breast cancer cell lines; the control group (normal cultured MCF-7/PTX cells), si-NC group, si-SNHG16 group, si-SNHG16+anti miR-NC group, and si-SNHG16 +anti-Let-7a-5p group were set to compared the effect of SNHG16 on the PTX resistance in MCF-7 cells; MTT assay, Flow cytometry, and Transwell invasion assay were used to determine the PTX resistance, apoptosis, and invasion ability of MCF-7 cells in different groups, respectively; for further assess the effect of SNHG16 on the PTX resistance, nude mouse tumor transplantation experiment was used; and the potential mechanism of SNHG16 regulated the PTX resistance in MCF-7 cells was explored by double luciferase reporter gene detection method and gene silencing technology. ResultsThe expression of SNHG16 gene and DUSP7 protein in MCF-7 cell line was the highest, and the expression of Let-7a-5p was the lowest compared with the various breast cancer cell lines (human breast epithelial cell line MCF-10A and human breast cancer cell lines MDA-MB-468 and MDA-MB-453) (P<0.05); PTX could increase the expression of SNHG16 gene and DUSP7 protein, and reduce the expression of Let-7a-5pin MCF-7 cell line (P<0.05); the results of cell experiment and nude mouse transplantation tumor experiment demonstrated that inhibiting the expression of SNHG16 gene could reduce the invasive ability and promote cell apoptosis of MCF-7/PTX cells (P<0.05), and inhibit tumor growth and reduce the PTX resistance in breast cancer transplantation models; simultaneous inhibition of Let-7a-5p and SNHG16 had a weakening effect in MCF-7/PTX cells (P<0.05). Double luciferase reporter gene detection and gene silencing technology demonstrated that inhibiting SNHG16 gene expression could increase the expression of Let-7a-5p and decrease the expression of DUSP7 (P<0.05); inhibiting the Let-7a-5p gene could increase the expression of DUSP7. ConclusionsInhibiting SNHG16 gene could upregulate Let-7a-5p expression and downregulate the expression of DUSP7 to inhibit MCF-7 cell invasion, promote MCF-7 cell apoptosis, and reduce the PTX resistance in MCF-7 cells and nude mouse tumor transplantation models, those data demonstrated that SNHG16-Let-7a-5p-DUSP7 axis maybe a potential therapeutic strategy for decreasing the PTX resistance in breast cancer in the future.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Zhao, H., Wang, L., Feng, Y., Yang, J.. 2023-08-19. LncRNA SNHG16 modulates paclitaxel resistance in breast cancer by regulating Let-7a-5p/DUSP7. https://doi.org/10.1101/2023.08.18.553807

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

m6A-Driven Intratumoral Cholesterol Biosynthesis Fuels Castration-Resistant Prostate Cancer Progression

Both nuclear pore complexes (NPCs) and RNA N6-methyladenosine (m6A) machinery are indispensable for proper cellular function. Although their collaborative roles in the nuclear export of messenger RNAs (mRNAs) have been reported, it remains ambiguous whether and how this collaboration may contribute to cancer progression. Here we identify a functional cooperation between NPCs and m6A signaling that promotes the development of castration-resistant prostate cancer (CRPC). We showed that nuclear export of m6A-modified mRNAs, mediated by the interaction between RNA methyltransferase METTL3 and the nucleoporin NUP93, is functionally coupled to cholesterol biosynthesis. Given that cholesterol-fueled intratumoral androgen production is one of the mechanisms driving CRPC, we demonstrated that overexpression of the wild-type METTL3 or NUP93, but neither the enzymatically dead METTL3 nor the mutant NUP93 that loses METTL3-interacting capability, elevates intracellular levels of androgens, activates AR signaling under castrate condition, and promotes androgen-independent growth of prostate cancer cells both in vitro and in vivo. Importantly, pharmacological inhibition of METTL3 or targeted demethylation on mRNAs encoding key cholesterol biosynthesis enzymes effectively suppressed CRPC malignancy. Together, these findings uncover a therapeutically targetable m6A-METTL3-NUP93 axis that links nuclear mRNA export and metabolic reprogramming to fuel CRPC progression, providing a conceptually new strategy for the treatment of this lethal disease.

cancer biology↗

ST6Gal2 promotes α2,6-sialylation and aggressive phenotypes in neuroblastoma cells

Neuroblastoma is the most common extracranial solid tumor of childhood. Its clinical behavior ranges from spontaneous regression to lethal, treatment-refractory disease. Aberrant 2,6-sialylation contributes to aggressive phenotypes in many cancers, but the role of ST6Gal2, a neural-enriched 2,6-sialyltransferase, in neuroblastoma is largely unexplored. Here, we examine the clinical and functional significance of ST6Gal2 in neuroblastoma. In two independent public cohorts (SEQC, n=498; Kocak, n=649), high ST6GAL2 expression was associated with significantly worse overall and event-free survival. In the SEQC cohort, ST6GAL2 expression was higher in high-risk and MYCN-amplified tumors, varied across International Neuroblastoma Staging System stages, and correlated positively with a mesenchymal transcriptional signature (Spearman {rho}=0.181). The mesenchymal correlation was reproduced in the Kocak cohort ({rho}=0.204). Stable shRNA-mediated knockdown of ST6GAL2 in SK-N-AS and SK-N-BE(2) cells reduced proliferation and viability, impaired wound closure, and decreased migration and invasion. In preliminary experiments in SK-N-AS cells, ST6GAL2 knockdown reduced binding of Sambucus nigra agglutinin, consistent with a role for ST6Gal2 in 2,6-sialylation. Together, these findings link ST6Gal2 expression to aggressive clinical and transcriptional features and pro-tumorigenic phenotypes in neuroblastoma and nominate ST6Gal2-mediated sialylation as a candidate pathway for mechanistic study.

cancer biology↗

Unsupervised transcriptomic analysis of paired pre- and post-treatment specimens reveals divergent chemoimmunomodulatory induction trajectories in breast cancer

The immunomodulatory effects of chemotherapy (chemoimmunomodulation; CIM) are clinically consequential and heterogeneous, yet no systematic framework exists for classifying the immunomodulatory trajectory a tumor follows in response to treatment (CIM trajectory). Here, we present the CIM Induction Classifier (CIMIC), an unsupervised clustering pipeline leveraging delta gene expression across 3,189 CIM-related genes to classify specimens chemoimmunomodulatory trajectory. Applied to two pre- and post-chemotherapy breast cancer (BC) datasets (NKI/SMC, N = 36; NEO, N = 19) and nine epirubicin-perturbed triple-negative BC (TNBC) cell lines, CIMIC identified two divergent CIM trajectories: a functional CIM (Fun-CIM) trajectory, broadly conserved across tumors and cell lines and characterized by induction of inflammatory cell death, antigen presentation, viral mimicry, and adaptive immune activation programs, and a dysfunctional CIM (Dys-CIM) trajectory, characterized by induction of proteostatic and metabolic stress-adaptation programs, reduced immune cell abundances and cytotoxic activity, and enrichment of aggressive BC subtypes. Using survival and longitudinal transcriptomic data in NKI/SMC (N = 20), treatment-induced increases in Fun-CIM-associated genes and ssGSEA scores were associated with reduced recurrence, whereas Dys-CIM-associated genes and scores were associated with increased recurrence. In multivariable analyses within independent chemotherapy-treated BC cohorts (METABRIC, N = 412; SCAN-B, N = 2,462), higher baseline Fun-CIM ssGSEA scores were associated with better outcomes, whereas higher baseline Dys-CIM ssGSEA scores were associated with worse outcomes. These findings establish CIM as a dynamic, trajectory-level process and position CIMIC as a framework for defining CIM trajectories and supporting future efforts to identify predictors, mechanisms, and therapeutic strategies that maximize beneficial CIM.

cancer biology↗